| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2613944636ab2fdf3f83ef2d4b304f0 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6809 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 |
| filingDate |
1990-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e8ad71fbbfe7fc812df26994111f56e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0804599a7dbc259f6691f32d1524c60f |
| publicationDate |
1991-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9101757-A1 |
| titleOfInvention |
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent |
| abstract |
The present invention relates to antitumor compounds of formula (I) wherein M is selected from the group consisting of an hydrogen atom, a peptide residue, and a protein residue linked to the carbon atom via the amino residue of ε-lysine present therein which can be an antibody used to target the anti-tumor agent to the malignant cells, and R can be an antitumor agent such as daunorubicin, doxorubicin or an epirubicin derivative. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6709679-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6310039-B1 |
| priorityDate |
1989-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |